Bio-Techne Corp TECH:NASDAQ

Last Price$468.74Cboe Real-Time Last Sale as of 1:00PM ET 12/01/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-3.29(0.70%)
Bid (Size)$468.25 (100)
Ask (Size)$469.56 (1)
Day Low / High$466.91 - 478.74
Volume139.5 K

View Biotechnology IndustryPeer Comparison as of 12/01/2021


Bio-Techne Corp ( NASDAQ )

Price: $468.74
Change: -3.29 (0.70%)
Volume: 139.5 K
1:00PM ET 12/01/2021

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $86.02
Change: -0.27 (0.31%)
Volume: 399.4 K
1:01PM ET 12/01/2021

Repligen Corp ( NASDAQ )

Price: $280.22
Change: -6.28 (2.19%)
Volume: 245.0 K
1:00PM ET 12/01/2021

Novavax Inc ( NASDAQ )

Price: $193.68
Change: -14.95 (7.17%)
Volume: 2.6 M
1:01PM ET 12/01/2021

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $184.64
Change: +0.84 (0.46%)
Volume: 161.3 K
1:01PM ET 12/01/2021

Read more news Recent News

Insider Sell: Bio-Techne
4:56PM ET 11/16/2021 MT Newswires

Norman David Eansor, President-Protein Sciences, on November 12, 2021, sold 27,159 shares in Bio-Techne (TECH) for $13,688,193. Following the Form 4 filing...

--Baird Adjusts Price Target on Bio-Techne to $548 From $522, Keeps Outperform Rating
10:34AM ET 11/03/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Bio-Techne Posts Higher Fiscal Q1 Adjusted Profit, Sales
7:18AM ET 11/02/2021 MT Newswires

Bio-Techne Corp (TECH) on Tuesday reported adjusted earnings of $1.83 per share in fiscal Q1, up from adjusted earnings of $1.43 per share a year ago. The...

-- Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q1 EPS $1.83
6:31AM ET 11/02/2021 MT Newswires


View all Commentary and Analysis

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q1 2022 Results - Earnings Call Transcript
2:52PM ET 11/02/2021 Seeking Alpha

Baron Funds Q3 2021 Andrew Peck Letter
2:46PM ET 10/27/2021 Seeking Alpha

The Landslide Portfolio
8:18PM ET 9/14/2021 Seeking Alpha

Tracking Ron Baron's BAMCO Portfolio - Q2 2021 Update
4:00AM ET 8/30/2021 Seeking Alpha

Company Profile

Business DescriptionBio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The co View company web site for more details
Address614 McKinley Place NE
Minneapolis, Minnesota 55413-2610
Number of EmployeesN/A
Recent SEC Filing11/23/20214
President, Chief Executive Officer & DirectorCharles R. Kummeth
CFO & Principal Accounting OfficerJames T. Hippel
Chief Medical OfficerRobert Monroe
Secretary & Chief Compliance OfficerBrenda Swierenga Furlow

Company Highlights

Price Open$473.76
Previous Close$472.03
52 Week Range$296.65 - 543.85
Market Capitalization$18.4 B
Shares Outstanding39.3 M
SectorHealth Technology
Current Dividend / Yield$0.32 / 0.27%
Dividend Ex-Date11/10/2021
Dividend Pay-Date11/26/2021
Dividend Yield 5 Year Average0.75%
Next Earnings Announcement02/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings109.35
Earnings per Share$5.56
Beta vs. S&P 500N/A
Revenue$714.0 M
Net Profit Margin17.93%
Return on Equity11.27%

Analyst Ratings as of 11/23/2021

Consensus RecommendationConsensus Icon
Powered by Factset